Breathe Free Lanka partners Novartis to provide Ultibro Breezhaler

• Once-daily maintenance solution for COPD patients

Breathe Free Lanka Ltd., a subsidiary of Cipla Ltd. has announced a partnership with Novartis for the marketing and distribution of Novartis’ Ultibro Breezhaler.

This partnership will enable Breathe Free Lanka to facilitate easy access to Ultibro Breezhaler for patients in Sri Lanka to help them alleviate specific debilitating symptoms of COPD. 

As part of this agreement, Novartis will be responsible for manufacturing Ultibro Breezhaler at its global facilities in line with its commitment to quality, effectiveness and safety.

This development is in line with Cipla’s aim of addressing unmet patient needs in respiratory and other therapy areas in Sri Lanka. The company has a strong record of focusing its efforts on improving healthcare and enhancing access to innovative medicines for improved disease management and better quality of life, especially for patients who currently do not have easy access to critical medicines.

Cipla International Business Europe and Emerging Markets CEO Nishant Saxena said: “As market leaders with significant presence in the respiratory segment, we look forward to leveraging our marketing and distribution strengths in Sri Lanka to take this product to as many patients as possible in furtherance of our purpose of ‘Caring for Life’.”

Novartis Singapore and Asian Emerging Markets Managing Director Celine Landie said: “Our partnership with Cipla is aligned with the Novartis commitment to address the unmet medical needs of COPD patients and improving their quality of life by providing innovative medicines and devices.”